Live from asco 2024 | ascentage pharma releases updated data of fak/alk/ros1 inhibitor apg-2449 in patients with nsclc

Suzhou, china, and rockville, md. , june 1, 2024 /prnewswire/ -- ascentage pharma (6855.hk), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis b (chb), and age-related diseases, announced today that it has released updated data of its novel drug candidate agp-2449, a fak/alk/ros1 tyrosine kinase inhibitor (tki), in patients with non-small-cell lung cancer (nsclc) in a poster presentation at the 60th american society of clinical oncology (asco) annual meeting taking place in chicago, il.
ALK Ratings Summary
ALK Quant Ranking